MTEM - Molecular Templates Inc Analyst Forecast Prices

Corporate company logo of Molecular Templates Corp (MTEM)

Molecular Templates (MTEM) delegates production and testing to external contractors to focus on therapy development. Business revenues are based on royalties and access fees for the ETB system used in the development of targeted toxins. However, the risk of bankruptcy due to funding shortages and program freezes is currently critical, with the metric standing at 17.97. This daily price chart for MTEM on the GURU.Markets platform clearly illustrates the current situation.

MTEM Molecular Templates, Inc. Price Target Chart (07/04/2022 - 12/28/2024)

Metric breakdowns and analytics for Molecular Templates Corp (MTEM)

- market price and analyst price targets:
Stock Quotes mtem.com|MTEM - Consensus Target
- market capitalization statistics:
Market Value Molecular Templates Corp|MTEM - Enterprise Value
- book capitalization information:
Net Asset Value per Share Molecular Templates|MTEM - Company Book Value|Market Cap to Net Assets Ratio mtem.com|MTEM - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Capital Molecular Templates|MTEM - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Molecular Templates Corporation|MTEM - Company Aggregate Debts|Debt to Book Value Molecular Templates Corp|MTEM - Company Long-Term Debt|Short-Term Debt Molecular Templates|Quick Liquidity mtem.com
- earnings and multiples data:
MTEM - Company Net Income|Expected Net Profit Molecular Templates|MTEM - P/E Multiple|Forward Price to Earnings Multiple Molecular Templates Inc|MTEM - Price/Earnings to Growth Multiple|Company Value to EBITDA Molecular Templates Corp|MTEM - Operating profit before deduction of amortization|Earnings per share for the trailing year Molecular Templates|MTEM - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months mtem.com|MTEM - Earnings per share growth in current year|Net earnings per share growth forecast for next year Molecular Templates
General company analysis:MTEM (mtem.com)
Mass-produced product of mtem.com

This indicator represents the weighted average expected value of the asset, synthesizing forecasts from industry experts to assess fair market value. By analyzing the trajectory of analysts' target prices, an investor can observe the dynamics of fundamental expectations, which for Molecular Templates (MTEM) critically depend on clinical trial outcomes and the patent protection of their unique targeted protein degradation platform.

Competitors of Molecular Templates

Consensus Target geron.com GERN|Nanobiotix - Consensus Target|Analyst Forecast Prices BCYC (Bicycle Therapeutics PLC)|CytomX Therapeutics Inc - Analyst Consensus Forecast|Average Forecast Price Perspective Therapeutics|genelux.com (GNLX) - Price Target Chart|Consensus Target Molecular Partners Ltd|Price Target Chart Oncolytics Biotech, Inc.|Average Forecast Price Lisata LSTA|Price Target Chart Moleculin Biotech, Inc. (MBRX)|galeratx.com - Broker Consensus Forecast